Article
Clinical Neurology
Jakub P. Hlavka, Jeffrey C. Yu, Darius N. Lakdawalla
Summary: This study presents a crosswalk between MMSE and TICS, providing a comparable cognitive measurement tool for adults aged 65 and older.
ALZHEIMERS & DEMENTIA
(2022)
Article
Behavioral Sciences
Feng-Feng Pan, Liang Cui, Qing-Jie Li, Qi-Hao Guo
Summary: A modified Chinese version of Mini-Addenbrooke's Cognitive Examination (C-MACE) was developed and showed good classification accuracy in detecting MCI. C-MACE performed best in identifying MCI in older individuals with lower education levels.
BRAIN AND BEHAVIOR
(2022)
Article
Neurosciences
Ge Wang, Alliyah Estrella, Ornin Hakim, Paul Milazzo, Sonali Patel, Clara Pintagro, Daniel Li, Rui Zhao, David E. Vance, Wei Li
Summary: This study compares the efficacy of MMSE and MoCA as cognitive monitoring tools and the correlation between the two tests. The results show that MMSE and MoCA are comparable for monitoring cognitive changes and have a moderate correlation for follow-up visits.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Clinical Neurology
Chien-Tai Hong, Hsun-Hua Lee, Chen-Chih Chung, Wei-Ting Chiu, Ting-Yi Lee, David Yen-Ting Chen, Li-Kai Huang, Chaur-Jong Hu, Lung Chan
Summary: This study aims to clarify the impact of ischemic stroke on poststroke cognitive impairment (PSCI) and compare its cognitive decline with Alzheimer's disease (AD). The results show that ischemic stroke substantially affects cognition, and the rate of cognitive decline in PSCI is similar to AD.
CURRENT ALZHEIMER RESEARCH
(2022)
Article
Neurosciences
Xiaoli Pan, Xiaoqin Cheng, Jie Zhang, Yingfeng Xia, Chunjiu Zhong, Guoqiang Fei
Summary: The five-minute cognitive test (FCT) is a novel and reliable method for detecting cognitive impairment at an early stage. This study analyzed the impact of sociodemographic and health-related factors on FCT performance and investigated its consistency. The results showed that FCT scores were influenced by age, education attainment, dwelling condition, and Body Mass Index. Additionally, FCT scores correlated significantly with specific neuropsychological tests.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Geriatrics & Gerontology
Yongkang Su, Jing Dong, Jin Sun, Yan Zhang, Shouyuan Ma, Man Li, Anhang Zhang, Bokai Cheng, Shuang Cai, Qiligeer Bao, Shuxia Wang, Ping Zhu
Summary: Cognitive impairment, reduced MMSE scores, and impaired MMSE domains are associated with an increased risk of all-cause mortality in Chinese elderly individuals.
Article
Geriatrics & Gerontology
Peter May, Celine De Looze, Joanne Feeney, Soraya Matthews, Rose Anne Kenny, Charles Normand
Summary: This study evaluated the predictive ability of Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) for high costs in Ireland. The findings showed that MoCA had superior predictive accuracy for high costs compared to MMSE, but the two scores identified slightly different types of high-cost users. Combining these two approaches may improve efforts to identify high-cost users in advance.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
(2022)
Article
Clinical Neurology
Che-Sheng Chu, I-Chen Lee, Chuan-Cheng Hung, I-Ching Lee, Chi-Fa Hung, Nai-Ching Chen
Summary: The study aimed to establish the validity and reliability of the Computerized Brief Cognitive Screening Test (CBCog) for early detection of cognitive impairment. Results showed that CBCog had high sensitivity and specificity in diagnosing MCI, especially in highly educated elderly individuals. The AUC of CBCog for discriminating between normal and MCI patients was higher than that of the MMSE.
CURRENT ALZHEIMER RESEARCH
(2021)
Article
Computer Science, Interdisciplinary Applications
Hezhe Qiao, Lin Chen, Fan Zhu
Summary: The study introduces a ranking convolutional neural network (rankCNN) method to predict MMSE through multi-classification, which outperforms other state-of-the-art methods on both ADNI-1 and ADNI-2 datasets. The proposed model achieved RMSE of 2.238 and 2.434 at baseline on the two datasets, demonstrating high prediction accuracy.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
(2022)
Article
Neurosciences
Nicolas Darmanthe, Hossein Tabatabaei-Jafari, Nicolas Cherbuin
Summary: This study aimed to evaluate the relationship between plasma neurofilament light chain (pNFL) and disease progression, finding that MCI patients with high pNFL levels are more likely to progress to AD dementia. Combining pNFL and MMSE can predict the risk of progression for patients within 5 years, with the addition of MMSE changes assessment further improving this predictive model.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Engineering, Biomedical
Eduardo Perez-Valero, Christian A. Morillas Gutierrez, Miguel Angel Lopez-Gordo, Samuel Lopez Alcalde
Summary: In this study, the potential of a visual dynamics evaluation called RSVP for detecting cognitive impairment in Alzheimer's disease (AD) was analyzed and compared with two commonly used cognitive tests in Spain. The preliminary results showed that the RSVP performance was significantly better in the control group compared to the patients, and the test exhibited high classification accuracy. This test can contribute to speeding up cognitive impairment screening and reducing associated costs.
JOURNAL OF NEUROENGINEERING AND REHABILITATION
(2023)
Article
Neurosciences
Knut Engedal, Jurate Saltyte Benth, Linda Gjora, Havard Kjesbu Skjellegrind, Marit Navik, Geir Selbaek
Summary: This study examined normative scores for the third Norwegian version of the MMSE and found that age and years of education influenced MMSE scores, with education being the strongest predictor.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Clinical Neurology
Sheridan D. Chappelle, Christina Gigliotti, Gabriel C. Leger, Guerry M. Peavy, Diane M. Jacobs, Sarah J. Banks, Emily A. Little, Douglas Galasko, David P. Salmon
Summary: Remote screening for cognitive impairment associated with Alzheimer's disease is important due to the aging population and possible treatment options. In this study, the Telephone Interview for Cognitive Status (TICS) and the telephone adaptation of the Montreal Cognitive Assessment (T-MoCA) were effective in detecting cognitive impairment remotely, and both tests correlated with AD biomarkers.
ALZHEIMERS & DEMENTIA
(2023)
Article
Neurosciences
Tom Ala, Danah Bakir, Srishti Goel, Nida Feller, Albert Botchway, Cindy Womack
Summary: This study aims to improve the ability to differentiate between AD and DLB by studying MMSE scores and including other dementia patients for perspective. The results suggest that the equation P minus M can effectively distinguish between AD and DLB, and it can also differentiate AD from Parkinson's disease dementia.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Neurosciences
Anna Marcisz, Joanna Polanska
Summary: This study aimed to find T1-weighted MRI-based markers for Alzheimer's disease and mild cognitive impairment (MCI) to improve screening. The proposed model achieved good results in detecting AD and improving MCI detection quality. The model can detect AD patients earlier than standard medical diagnosis.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Geriatrics & Gerontology
Blossom C. M. Stephan, Graciela Muniz-Terrera, Antoneta Granic, Joanna Collerton, Karen Davies, Brian K. Saxby, Keith A. Wesnes, Thomas B. L. Kirkwood, Carol Jagger
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
(2018)
Article
Geriatrics & Gerontology
J. Huntley, A. Corbett, K. Wesnes, H. Brooker, R. Stenton, A. Hampshire, C. Ballard
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
(2018)
Review
Cell Biology
Sophie Miguel, Claire Champ, Jon Day, Esther Aarts, Ben A. Bahr, Martijntje Bakker, Diana Banati, Vittorio Calabrese, Tommy Cederholm, John Cryan, Louise Dye, Jonathan A. Farrimond, Aniko Korosi, Sophie Laye, Stuart Maudsley, Dragan Milenkovic, M. Hasan Mohajeri, John Sijben, Alina Solomon, Jeremy P. E. Spencer, Sandrine Thuret, Wim Vanden Berghe, David Vauzour, Bruno Vellas, Keith Wesnes, Peter Willatts, Raphael Wittenberg, Lucie Geurts
AGEING RESEARCH REVIEWS
(2018)
Article
Neurosciences
A. W. Watson, E. J. Okello, H. J. Brooker, S. Lester, G. J. McDougall, K. A. Wesnes
NUTRITIONAL NEUROSCIENCE
(2019)
Article
Geriatrics & Gerontology
Irem Ece Eraydin, Christoph Mueller, Anne Corbett, Clive Ballard, Helen Brooker, Keith Wesnes, Dag Aarsland, Jonathan Huntley
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
(2019)
Review
Pharmacology & Pharmacy
Alette M. Wessels, Chris J. Edgar, Pradeep J. Nathan, Eric R. Siemers, Paul Maruff, John Harrison
Summary: Making Go/No-Go decisions in early phase clinical trials for Alzheimer's disease drugs is challenging due to recent negative trial results linked to lack of efficacy and safety concerns. Demonstrated target engagement rarely translates to clinical efficacy, highlighting the importance of cognitive data for decision making criteria in drug development, varying based on the context like stage of development, mechanism of action, and trial design.
DRUG DISCOVERY TODAY
(2021)
Article
Neurosciences
Chris J. Edgar, Eric Siemers, Paul Maruff, Ronald C. Petersen, Paul S. Aisen, Michael W. Weiner, Bruce Albala
Summary: The study evaluated the feasibility of at-home, self-completion of the CBB in the ADNI over 24 months, showing potential for use in MCI groups. However, data collection declined over time, suggesting the need for strategies to maintain compliance.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Clinical Neurology
Jessica B. Langbaum, Julie Zissimopoulos, Rhoda Au, Niranjan Bose, Chris J. Edgar, Evan Ehrenberg, Howard Fillit, Carl Hill, Lynne Hughes, Michael Irizarry, Sarah Kremen, Darius Lakdawalla, Nancy Lynn, Kristina Malzbender, Tetsuyuki Maruyama, Holly A. Massett, Deep Patel, Desi Peneva, Eric M. Reiman, Klaus Romero, Carol Routledge, Michael W. Weiner, Stacie Weninger, Paul S. Aisen
Summary: Clinical trials for Alzheimer's disease face challenges in recruiting study participants, with slow enrollment, long completion time, and high costs. In 2020, an advisory panel of experts from various fields convened to assess the critical challenges in recruitment and develop recommendations to accelerate the development of novel therapies for AD.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Emma Borland, Chris Edgar, Erik Stomrud, Nicholas Cullen, Oskar Hansson, Sebastian Palmqvist
Summary: The study established minimal clinically important differences for commonly used cognitive tests using different methods and investigated a composite cognitive measure for predicting changes in Clinical Dementia Rating-Sum of Boxes. Results identified potential MCIDs for different cognitive tests and found a composite measure including gender and changes in specific tests as the best predictor for changes in CDR-SB, with an AUC of 0.87.
Meeting Abstract
Hematology
David J. Kuter, Umer Khan, Paul Maruff, Chris Edgar, Jason Cromer, Gabe Stellman, Lydia King, Kathie Markowski, Ahmed Daak
Article
Clinical Neurology
E. Siemers, J. Hitchcock, K. Sundell, R. Dean, J. Jerecic, E. Cline, K. Iverson, J. Moore, C. Edgar, R. Manber, N. Fuin, T. Poppe, R. Barton
Summary: ACU193 is a potential treatment for Alzheimer's disease that is currently undergoing phase 1 clinical trials. The study design incorporates novel biomarkers and adaptive study designs to accelerate the development process.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2023)
Article
Clinical Neurology
Dorene M. Rentz, Alette M. Wessels, Ananth V. Annapragada, Anna-Karin Berger, Chris J. Edgar, Michael Gold, David S. Miller, Christopher Randolph, J. Michael Ryan, Glen Wunderlich, Megan Canniere Zoschg, Dominic Trepel, David S. Knopman, Adam M. Staffaroni, Lisa J. Bain, Maria C. Carrillo, Christopher J. Weber
Summary: The Research Roundtable discussed the lack of consensus on defining clinical meaningfulness at different stages. Participants engaged in discussions about various approaches to defining clinical meaningfulness from different perspectives.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
(2021)
Article
Health Care Sciences & Services
Joshua P. White, Adrian Schembri, Chris J. Edgar, Yen Ying Lim, Colin L. Masters, Paul Maruff
Summary: By reducing test difficulty, OCL48 shows a higher sensitivity to memory impairment in AD compared to OCL80, with better performance in terms of ceiling effects and practice effects.
FRONTIERS IN DIGITAL HEALTH
(2021)
Article
Clinical Neurology
Fiona McDougall, C. Edgar, M. Mertes, P. Delmar, P. Fontoura, D. Abi-Saab, C. J. Lansdall, M. Boada, R. Doody
Summary: This study investigated the psychometric properties of commonly used efficacy measures in a clinical trial of prodromal AD. The CDR-SB demonstrated good psychometric properties in prodromal AD, supporting its continued use in clinical trials. There is still room for improvement in assessing functional constructs, and the development of novel measures should continue.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2021)
Article
Clinical Neurology
C. J. Edgar, G. Vradenburg, J. Hassenstab
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2019)
